VJVirtual | Changing management of thoracic malignancies as a result of the COVID-19 pandemic

Sanjay Popat, BSc, MBBS, FRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, discusses changes in the management of thoracic malignancies as a result of the COVID-19 pandemic. These include use of pegylated GCSF to minimise neutropenia, the recommendation of infrequent chemotherapy regimes as well as the approval of osimertinib as first line treatment for EGFR mutant lung cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).